Acalabrutinib Could Be Particularly Impactful for Long-Term Treatment Perspectives in CLL

In an interview with Pharmacy Times, Niko Andre, MD, PhD, global franchise head of hematology and immuno-oncology at AstraZeneca, discussed exciting new findings being presented at the American Society of Hematology 2021 Annual Meeting about adverse effects associated with acalabrutinib in patients with chronic lymphocytic leukemia (CLL).

Because many patients with CLL could have the disease for up to a decade, Andre said acalabrutinib could offer a high level of confidence for patients looking at a long course of disease. Furthermore, he said that based on current data acalabrutinib is a clear choice for patients with CLL, regardless of their demographic factors.